Crossref
EE353 COST-EFFECTIVENESS ANALYSIS OF UBLITUXIMAB FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS
Value in Health · 2026-06 · 29 (6) · S130
DOI: 10.1016/j.jval.2026.03.647 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Susmita R. Riya und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Riya, S. R., & Kamal, K. M. (2026). EE353 COST-EFFECTIVENESS ANALYSIS OF UBLITUXIMAB FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS. Value in Health, 29(6), S130. https://doi.org/10.1016/j.jval.2026.03.647
Vancouver
Riya SR, Kamal KM. EE353 COST-EFFECTIVENESS ANALYSIS OF UBLITUXIMAB FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS. Value in Health. 2026;29(6):S130. doi:10.1016/j.jval.2026.03.647
BibTeX
@article{Riya2026,
author = {Riya, Susmita R. and Kamal, Khalid M.},
title = {EE353 COST-EFFECTIVENESS ANALYSIS OF UBLITUXIMAB FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {6},
pages = {S130},
doi = {10.1016/j.jval.2026.03.647}
}
EUVIMED